Hangzhou Jiuyuan Gene Engineering Co Ltd

02566

Company Profile

  • Business description

    Hangzhou Jiuyuan Gene Engineering Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, It has built a diversified product portfolio comprising eight marketed products, including China’s first recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair material, Guyoudao, and over ten product candidates, including the first semaglutide biosimilar in China to have obtained an IND approval and filed an NDA, JY29-2.

  • Contact

    No. 23, Eighth Street Baiyang Street
    Qiantang District
    Zhejiang Province
    Hangzhou
    CHN

    T: +86 57186910099

    https://www.china-gene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,467

Stocks News & Analysis

stocks

2 undervalued ASX shares report

These two ASX shares are trading at a discount to our fair value. 
stocks

Turmoil at WiseTech

Board members step down over differences on the role of former CEO Richard White.
video

What does the RBA rate cut mean for investors?

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,498.0062.10-0.73%
CAC 408,090.9963.52-0.78%
DAX 4022,425.93138.370.62%
Dow JONES (US)43,461.2133.190.08%
FTSE 1008,658.980.39-0.00%
HKSE23,227.63113.98-0.49%
NASDAQ19,286.93237.08-1.21%
Nikkei 22538,281.45495.49-1.28%
NZX 50 Index12,307.27224.45-1.79%
S&P 5005,983.2529.88-0.50%
S&P/ASX 2008,251.9056.30-0.68%
SSE Composite Index3,367.255.77-0.17%

Market Movers